Brief: Corline Biomedical Signs Agreement For Phase 2 Study In Kidney Transplantation
June 13 (Reuters) - Corline Biomedical AB CLBIO.ST :
* SIGNS AGREEMENT WITH CRO SUPPLIER FOR PHASE 2 STUDY IN
KIDNEY
TRANSPLANTATION AND ADDS SUPPLIER OF DRUG SUBSTANCE
* EXPECTS TO INITIATE THE FIRST TRANSPLANT CLINICS IN EUROPE
IN
LATE Q3 2022
* EXPECTS DELIVERY OF DRUG SUBSTANCE FOR THE STUDY TO OCCUR
IN Q4
2022
Source text for Eikon: ID:nGNEbyj21b
Further company coverage: CLBIO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Corline Biomedical AB
See all newsBrief: Corline Biomedical Expectes Positive EBITDA In 2027
Brief: Corline Biomedical: Canada To Grant Kardium Up To C$31.25 Mln For Manufacturing Capacity Expansion
Brief: Corline Biomedical Q2 Net Sales Amount To SEK 4.7 Million
Brief: Corline Biomedical Partner Kardium Receives Approval For Globe Pulsed Field System In Canada
Brief: Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln